Lineage outlines cash runway into Q3 2028 while targeting COR1 in vivo data by year-end (NYSE:LCTX)

Lineage Cell Therapeutics (LCTX) Q2 2026 earnings call: OpRegen, AlloSCOPE/Lineage 3.0 pipeline, cash runway to Q3 2028 & catalysts—read now.

Lineage outlines cash runway into Q3 2028 while targeting COR1 in vivo data by year-end (NYSE:LCTX) | Seeking Alpha

Earnings Call Insights: Lineage Cell Therapeutics (LCTX) Q2 2026

Management View

"Insights and milestones from the OpRegen program have allowed us to fuel the growth of a new and significantly more internally owned pipeline of cell therapy assets." (CEO, President & Director Brian Culley)

Seeking Alpha's Disclaimer:

This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please

report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Search field

Entering text into the input field will update the search result below

Quick Insights

What are the main growth drivers for Lineage Cell Therapeutics' internal pipeline?

Growth is being driven by the AlloSCOPE platform, a new internally owned pipeline expansion (Lineage 3.0), development of assets like COR1, ILT1, ReSonance, and a partner-funded OPC1 focus shift.

How does management view progress and risks for OpRegen's advancement?

Management remains confident in OpRegen's progress towards a multicenter trial but notes timelines depend on partners (Roche/Genentech); recent milestones include EMA database registration, GAlette site expansion, but staffing tone is more guarded on details and partner timelines.

What is Lineage Cell Therapeutics' current financial position and operating runway outlook?

As of the call, Lineage has $50.8 million in cash, expecting to fund operations into Q3 2028. This quarter's net income mainly resulted from noncash warrant-liability changes, not cash-generating business activity.

Recommended For You

More

Trending News

See More

»